MiGenTra Egypt is the first and largest biotech process R&D and biomanufacturing facility in Egypt, Africa, and the Middle East. The company specializes in the process development and end-to-end manufacturing of therapeutic recombinant proteins with a primary focus on the areas of liver disease, thrombosis and haemostasis, infertility, oncology, as well as rheumatoid arthritis. The company’s first and foremost goal is to provide patients with highly innovative and affordable genetically engineered recombinant drugs with the highest standard of quality. MiGenTra Egypt has already developed and is manufacturing 10 therapeutic recombinant proteins.
